It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Our preclinical formulation services are designed to reduce risk during lead optimization and selection. With deep expertise in solid-state and formulation science, we create tailored solutions that support your pharmacology and toxicology studies, setting your molecule up for success.
Solid form and formulation are tightly interlinked, each influencing bioavailability, stability, and in vivo performance.
At Sygnature Discovery, we integrate solid-state characterization with formulation design to build a strategy tailored to your compound. Our focus on well-tolerated, long-term dosing formulations helps reduce risk during lead optimization and ensures your molecule is ready for in vivo studies.
What we offer:
• Formulation screening and development for small molecules and peptides
• Conventional and advanced technologies to enhance solubility, stability, and exposure
• Fast design–make–test cycles through co-location with DMPK and in vivo pharmacology
• Expertise across multiple dosing routes: oral, IV, IM, IP, SC, intranasal and inhalation
• Species coverage includes rodents (mice, rats), dogs, mini-pigs, rabbits, and non-human primates
Our state-of-the-art labs and responsive scientists work closely with you to meet specific goals – whether it’s achieving high drug loading, boost in bioavailability, linear PK, or well-tolerated formulations. We’re committed to helping your molecule progress from bench to clinic.
Formulation Screening
We offer a range of preclinical services to design custom formulations that maximize exposure and support linear pharmacokinetics:
Solid -State Characterization
Understand how solid form– amorphous or crystalline- affects formulation performance, stability, and morphology.
Lipid -Based Formulations & ASDs
Develop oral lipid-based formulations (SEDDS/SNEDDS) and amorphous spray-dried dispersions (ASDs) to boost in vivo performance
Permeation-Enhancer Suite
Improve absorption when permeability limits bioavailability.
Liposomal Formulations
Use our liposomal screening platform to reduce toxicity, enhance delivery, and create IP opportunities.
Parenteral Formulations
Develop long acting injectables, nanosuspensions and solutions for SC, IM, IV administration.
Lyophilized Formulations
Creates table IV or inhalation formulations for poorly soluble candidates and nebulization.
in vitro & Analytical Support
• in vitro lipolysis to rank or optimize oral lipidic systems
• Dissolution and flux measurement using Pion μDiss profiler in biorelevant media to predict animal PK
• Stability testing under ICH-like conditions (25°C/60%RH and 40°C/75%RH)
Why Choose Sygnature Discovery for Pre-Clinical Formulation Support?
We offer a comprehensive, phase-appropriate formulation service for both integrated and stand-alone drug discovery programs. Our co location with DMPK and in vivo pharmacology enables rapid design–make–test analyze cycles, accelerating your path to IND filing and first-in-human studies. With deep expertise in solid state science and formulation, we ensure your compound is ready for preclinical success whether your route is oral, injectable, or inhalation.
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule’s clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Sygnature has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at…
News
FAQs
A phase-appropriate formulation is tailored to the specific needs of development such as preclinical studies—focusing on tolerability, exposure, and simplicity to support rapid progression.
Typically, we aim to deliver a couple of stable formulations within 5-6 weeks of signing off on work and we can work with less than 300mg of compound.
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
